Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences Co., Ltd. announced the acceptance of its new drug application for Roconkibart Injection by the National Medical Products Administration. This drug, aimed at treating moderate to severe plaque psoriasis, has shown significant efficacy in clinical trials and represents a potential advancement in the treatment of autoimmune diseases, enhancing the company’s position in the pharmaceutical industry.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a pharmaceutical company based in China, focusing on the development of innovative drugs. The company specializes in monoclonal antibodies and targets autoimmune diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis.
Average Trading Volume: 5,539,372
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.37B
Find detailed analytics on 1877 stock on TipRanks’ Stock Analysis page.